CBOE : BINV
-$0.05 (-0.11%)
| Source | Headline |
|---|---|
|
BioInvent International AB: Interim Report January - March 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent. accessnewswire.com - 2026-04-29 02:20:00 |